Story thread · 26 reports / 12 sources
Sleep drug developer Apnimed rises on trading debut
seekingalpha.com · 11d
How the coverage leans
Across 12 sources · syndicated copies counted once
First report: Reformation prices IPO at $15 per share on NYSE — investing.com, 13d
The coverage
- Sleep-Apnea Biotech Apnimed Shares Jump After Upsized US IPO
bloomberg.com · 11d
- Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
endpts.com · 11d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.